People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 121 participants.

Also called NCT03520660

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03520660
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03520660. Non-randomized; no masking; primary purpose treatment. Start 2018-10-19 (actual); primary completion 2032-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Condition
Diabetes Mellitus
Condition
Hepatitis C, Chronic
Condition
Cardiovascular Diseases
Intervention (Drug)
Epclusa
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03520660
Content hash
a190372947a70579787bea34d93ae7879889a699b4184c2ea2e544d2be2b9647